Congenital pulmonary lymphangiectasis.

Friedrich Reiterer, Karin Grossauer, Nicholas Morris, Sabine Uhrig, Bernhard Resch

Journal: Paediatric respiratory reviews 2016;15(3):275-80

PMID: 24997116

Abstract

Congenital pulmonary lymphangiectasis (CPL) is a rare vascular malformation causing dilated lymph vessels and disturbed drainage of lymph fluid. Based on the pathogenesis and clinical phenotype it can be classified as primary or secondary CPL. Associated genetic syndromes with or without lymphedema, familial occurrence and gene mutations have been described. In utero, it may present as non-immune hydrops with pleural effusions. At birth neonates may have respiratory failure due to chylothorax and pulmonary hypoplasia, causing very high short term mortality rates. Other cases may become symptomatic any time later in childhood or even during adult life. CPL is usually diagnosed based on the combination of clinical signs, imaging and histological findings. Open-lung biopsy is considered the gold standard for the diagnosis of CPL. Treatment is primarily supportive featuring aggressive mechanical ventilation and the management of problems associated with congenital chylothorax including chest-drainage, medium-chain triglycerides (MCT) diet, and octreotide.

Copyright © 2014 Elsevier Ltd. All rights reserved.

Address: Division of Neonatology, Department of Paediatrics, Medical University of Graz, Austria. Electronic address: [email protected].; Division of Neonatology, Department of Paediatrics, Medical University of Graz, Austria.; Institute of Human Genetics, Medical University of Graz, Austria.; Division of Neonatology, Department of Paediatrics, Medical University of Graz, Austria; Research Unit for Neonatal Infectious Diseases and Epidemiology, Medical University of Graz, Austria.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.